• Explore /
  • Poster
  • / Phase II trial of dabrafenib and trametinib in patients with BRAFV600E/R or non-BRAFV600 mutated advanced solid tumors: Results from the BELIEVE trial (NCCH1901).

Phase II trial of dabrafenib and trametinib in patients with BRAFV600E/R or non-BRAFV600 mutated advanced solid tumors: Results from the BELIEVE trial (NCCH1901).

Abstract Poster

Authors

Makoto Tahara

Makoto Tahara

National Cancer Center Hospital East, Japan, Kashiwa-Shi, Japan

Makoto Tahara , Tatsunori Shimoi , Satoshi Nishiwaki , Shota Tanaka , Eishi Baba , Manabu Muto , Ichiro Kinoshita , Daisuke Sakai , Masahiro Tabata , Hideyuki Hayashi , Chikashi Ishioka , Nobuaki Mamesaya , Noboru Yamamoto

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Clinical Trial Registration Number

jRCTs031190104

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3096)

DOI

10.1200/JCO.2023.41.16_suppl.3096

Abstract #

3096

Poster Bd #

294

Abstract Disclosures

Similar Posters

First Author: Gregory J. Riely

First Author: Gil Awada

First Author: Alain Patrick Algazi

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Phase Ib study of dabrafenib, trametinib, irinotecan and cetuximab in BRAF V600E-mutated metastatic colorectal cancer.

Phase Ib study of dabrafenib, trametinib, irinotecan and cetuximab in BRAF V600E-mutated metastatic colorectal cancer.

First Author: Yungchang Chen